Real‐World Experience With Control‐IQ Technology in Saudi Children With Insulin‐Dependent Diabetes: A Single‐Center Observational Study
Pediatric Diabetes · 2026-01 · 2026 (1)
DOI: 10.1155/pedi/6113065 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Diabetes, online erschienen am 01.03.2026. Verfasst von Afaf Alsagheir und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, kfshrc.edu.sa. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Insulin, Hypoglycemic Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
The Tandem t:slim X2 insulin pump with the Control‐IQ technology (Control‐IQ) is an automated insulin delivery (AID) system for glycemic control but has limited data in Saudi pediatric and young adult populations. We aim to evaluate the efficacy and safety of Control‐IQ therapy in children with insulin‐dependent diabetes and previously treated with multiple daily injections (MDIs). The primary outcome is to assess the change in HbA1c 6 months after initiating Control‐IQ technology.
Methods
This prospective observational study evaluated children aged 2–14 years with insulin‐dependent diabetes who transitioned from treatment with MDI to the Control‐IQ technology in the diabetes clinic at the King Faisal Specialist Hospital and Research Centre (KFSHRC) in Saudi Arabia.
Results
A total of 100 patients (44 boys and 56 girls; median age was 11 years) were included. Most (82%) had a history of severe hypoglycemia. Following Control‐IQ initiation, median HbA1c significantly decreased from 9.2% to 6.9% at 6 months (−25.0%; p < 0.001), accompanied by a 24.4% reduction in the daily insulin dose. Time in range (TIR) (70–180 mg/dL) improved from 45.6% to 68.8% (+23.2%; p < 0.001), while time in significant hypoglycemia (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, kfshrc.edu.sa.
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia, alfaisal.edu.
- Department of Nursing Development and Saudization, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, kfshrc.edu.sa.
- Department of Diabetes Education, VitalAire Arabia Company, Riyadh, Saudi Arabia.
ORCID-Profile: Afaf Alsagheir, Bassam Bin-Abbas, Razan Alsagheir, Raghad Alhuthil, Aseel Aljuwair, Norah H Alobailly, Sheikhah Almoaily
Zitieren
APA
Alsagheir, A., Bin-Abbas, B., Alsagheir, R., Alhuthil, R., Aljuwair, A., Alobailly, N. H., & Almoaily, S. (2026). Real‐World Experience With Control‐IQ Technology in Saudi Children With Insulin‐Dependent Diabetes: A Single‐Center Observational Study. Pediatric Diabetes, 2026(1). https://doi.org/10.1155/pedi/6113065
Vancouver
Alsagheir A, Bin-Abbas B, Alsagheir R, Alhuthil R, Aljuwair A, Alobailly NH, et al. Real‐World Experience With Control‐IQ Technology in Saudi Children With Insulin‐Dependent Diabetes: A Single‐Center Observational Study. Pediatric Diabetes. 2026;2026(1). doi:10.1155/pedi/6113065
BibTeX
@article{Alsagheir2026,
author = {Alsagheir, Afaf and Bin-Abbas, Bassam and Alsagheir, Razan and Alhuthil, Raghad and Aljuwair, Aseel and Alobailly, Norah H and Almoaily, Sheikhah},
title = {Real‐World Experience With Control‐IQ Technology in Saudi Children With Insulin‐Dependent Diabetes: A Single‐Center Observational Study},
journal = {Pediatric Diabetes},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/pedi/6113065}
}
EUVIMED